Myelodysplastic Syndrome (MDS) Clinical Trial
Official title:
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With RAEB-1 AND RAEB-2 Myelodysplastic Syndrome (MDS) and AML With Trisomy 8
This study will determine the highest dose of the experimental drug ON 01910.Na that can
safely be given to patients with the bone marrow disorder myelodysplasia (MDS) and patients
with refractory AML with trisomy 8. In this disease, the bone marrow can make some blood
cells, but very few of these cells are released into the blood for use in the body. ON
01910.Na is an experimental drug that inhibits a protein called cyclinD1that is important for
keeping MDS cells alive. In laboratory experiments, ON 01910.Na has acted against cyclinD1,
causing MDS cells to die. The study will also evaluate how the body handles ON 01910.Na, the
effect of the drug on MDS and AML and its side effects.
Patients 18 to 85 years old with MDS or AML who do not have a suitable sibling donor for a
marrow transplant or who are not willing to have a transplant may be eligible for this study.
Participants receive ON 01910.Na in 2-week treatment cycles, with 3 to 5 days of drug
infusion through a vein followed by 9 to 11 days of observation. To find the highest safe
dose of ON 01910.Na, the first person enrolled in the study is given the smallest study dose
of the drug for 3 days, followed 2 weeks later with a second dose for 3 days. If these doses
are found safe, the next two people receive the same dose. If these subjects do well, the
next group of patients receives the next higher dose level. The dose continues to be
increased in groups of 3 to 6 subjects until the fourth and highest dose level is reached.
Patients who do well on the treatment may receive an additional six cycles of ON 01910.Na (3
to 5 days of infusion once every other week for 12 weeks).
Before, during and after the treatment period, patients are periodically evaluated and
monitored with the following tests and procedures:
- Physical examination and review of medical and medication history.
- Blood and urine tests.
- Pregnancy test for women of childbearing age.
- Electrocardiogram (EKG) and chest X-ray.
- Bone marrow biopsy.
The myelodysplastic syndromes (MDS) and acute myelogenous leukemias (AML) are a group of
heterogeneous diseases with wide variation in clinical presentation and disease severity.
Typically patients are older adults with co-morbidities. AML and MDS are characterized by
variable degrees of cytopenias (anemia, neutropenia, thrombocytopenia) due to ineffective
hematopoiesis and dysplastic bone marrow morphology or hematological malignancy.
Treatment of MDS is unsatisfactory: chemotherapy has a limited role in the management of
leukemic progression; autologous stem cell transplantation does not prolong relapse-free
survival and stem cell transplantation is poorly tolerated in older individuals. Some MDS
patients have been shown to respond to a wide variety of immunosuppressive agents ranging
from corticosteroids to cyclosporine (CsA) and horse antithymocyte globulin (h-ATG). However,
the overall response rate is less than 30% and relapse continues to be a problem. Few
treatments appear to change the natural history of MDS however, growth factors, decitabine,
and lenalidomide can improve cytopenias, and 5-azacytidine, can reduce transfusion
requirements, and improve quality of life when compared to supportive care. In addition most
MDS patients are older and tolerate aggressive therapies poorly.
Some AML patients can be cured with chemotherapy or by allogeneic stem cell transplantation.
However standard treatment approaches are not effective for patients who become refractory to
chemotherapy, elderly patients, and those who relapse after transplantation.
The management of MDS and relapsed/refractory AML patients therefore remains unsatisfactory
and targeted therapies are needed. One such investigational drug, ON 01910.Na, is a potent
inhibitor of cyclin D1 and mitosis. ON01910.Na shows activity against a broad spectrum of
tumor cell lines. Animal model studies show little toxicity with a high therapeutic index in
these tumors. In addition, the fact that MDS bone marrow (particularly trisomy 8) and
patients with AML with the trisomy 8 abnormality (Sloand, unpublished data) over-express
cyclin D1 and in vitro studies have demonstrated activity against cytogenetically abnormal
cells and blasts despite minimal inhibition of normal hematopoiesis provides a rationale for
its use in select patients with MDS or AML.
We therefore propose a non-randomized, pilot, dose escalating Phase I study of ON 01910.Na in
MDS and patients with refractory AML with trisomy 8.
The primary objective is to determine the safety (including the maximum tolerated dose and/or
dosing regimen) of ON 01910.Na when administered in escalating doses in select patients with
MDS or AML. Secondary objectives include plasma pharmacokinetics and biological effects of ON
01910.Na on cell-cycle pathways of MDS or AML cells, and bone marrow RNA analysis to assess
if gene expression can predict clinical response to ON 01910.Na in subjects with MDS.
The primary endpoint will be the toxicity profile at each dose level. Secondary endpoints
will include the evaluation of early evidence of disease response by blast and cytogenetic
improvement.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
Suspended |
NCT01211691 -
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06294275 -
A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT04401748 -
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
|
Phase 3 | |
Recruiting |
NCT04608110 -
A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
Withdrawn |
NCT03486353 -
A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome
|
Phase 2 | |
Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
Terminated |
NCT01459159 -
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
|
Phase 2 | |
Terminated |
NCT01422486 -
Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome
|
Phase 2 | |
Terminated |
NCT00542828 -
Rabbit Anti-thymocyte Globulin in the Treatment of Patients With Low to Intermediate-1 Risk Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
Recruiting |
NCT01861093 -
Safety Study of Cord Blood Units for Stem Cell Transplants
|
Phase 2 | |
Unknown status |
NCT01983761 -
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
Completed |
NCT01338337 -
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
|
Phase 2 | |
Completed |
NCT01221857 -
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT01034657 -
LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 |